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Dr John F. Eidt (Little Rock, Ark). This is indeed a unique
randomized trial comparing above knee synthetic bypass to the
Gore stent graft. Of note, the authors report comparable perfor-
mance between these two treatment groups at 4 years. There is a
trend favoring stent grafts larger than 5 mm in diameter.
There are still important questions regarding endograft treat-
ment of the SFA. 1) Stent grafts result in the loss of all collateral
vessels in the covered segment. 2) The unsheathed design exposes
the relatively rough outer texture of the delivery system to the
arterial wall, may result in so-called “snow-plowing,” and may risk
damage to the draw string release mechanism. 3) For entry into
this trial, flush occlusions of the SFA were excluded, which elimi-
nates one of the issues with Viabahn related to precise location of
the proximal end of the stent graft in proximity to the profunda
femoris. 4) Some surgeons have been concerned that thrombosis
of the stent graft may result in deterioration of runoff with a need
for more distal target at the time of conversion – a worry that was
not substantiated by your data. 5) You have noted in your manu-
script a higher amputation rate in the bypass group though, in
fairness, in two cases the grafts remained patent at the time of
amputation. In addition, there were more than twice as many
Rutherford class 4, 5, and 6 patients in the bypass arm of the trial
(9 vs 19). 6) There were a variety of antithrombotic regimens;
almost all (93%) of the stent graft patients were on combination
antiplatelet therapy with aspirin and plavix in comparison to only
about half of the bypass patients.
I have three questions:
1. The patients included in this trail had relatively mild lesions.
More than 70%were TASC II A and B lesions, meaning that the
maximum length was less than 15 cm. The Resilient trial
documented 12-month patency of more than 80% for a bare
nitinol stents in TASC A and B lesions. Further, in thethere was no difference between bare nitinol stents and Viabahn
at 1 year with primary patency of only around 55%. My ques-
tion: is Viabahn better than bare nitinol? Is it worth the addi-
tional cost?
2. You also have shown statistically what many have us have
observed; if you get through the first year or so, you are likely to
de well long-term. When grafts fail, it appears to be unpredict-
able. What is your current recommendation for ultrasound
surveillance in these patients? Did you identify failing grafts and
intervene prior to graft failure?
3. If I understand your numbers, of the 46 bypass patients, 15
were lost to follow up and 8 died leaving 23 patients. Of these,
there were 16 graft failures. In the stent graft group, of 40
patients, 6 were lost and 9 died, leaving 25 patients with 18
stent graft failures. Now it is possible that all those lost to follow
up were lost because they were doing well, but I suspect that at
least some of these patients wound up in the offices of other
vascular surgeons. In a population of predominately TASC A
and B lesions with mostly intermittent claudication, are these
results really good enough?
Dr Karen McQuade (Dallas, Tex). Thank you, Dr Eidt, for
your questions. To answer your first question, yes, we did exclude
flush occlusions. The patient had to have at least 1 cm of good
artery proximally for stent graft landing. The second question
addressed our TASC classification. I would point out that we
initially enrolled and we did use TASC I classification for our target
lesions characteristics, but here in our follow-up study, we have
used TASC II criteria, and remember, a TASC II B lesion can
include occlusions up to 15 cm, so a lot of these patients would
have been a TASC I C or D classification, whereas they have now
have been reclassified as a Class II B lesion. I think that many
studies are currently still using TASC I criteria for their classifica-
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 3 McQuade et al 591tion reporting so that might explain some of the difference there.
The RESILIANT study addressed much shorter lesions less than
10 cm at only 24-month follow up.
For follow-up purposes, we followed these patients every 3
months with duplex ultrasound for the first year, then every 6
months if there were no identified issues. Any graft identified with
a significant stenosis was reported as a failure, so none of the patent
grafts were intervened on. One of your questions discussed the use
of our stent grafts and claudicants. In our practice, we do recom-recommend best medical management, exercise therapy, and
smoking cessation for claudicants; however, for those patients who
fail these modalities or who are unable to perform their activities in
daily living, we consider intervention on these patients, and we do
give consideration to reconstruction with stent grafts for these
patients. I believe in terms of whether our patency rates we are
reporting here are good enough, I think that each patient is an
individual, that each treating physician is an individual, and we
offer this data for you to use in your decision making for treatmentmend initially non-interventional treatment for claudicants. We of these patients.
